Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 126-134

  Therrien, Frédérick ^a   Lemieux, Pierre ^a   Bélanger, Simon ^a   Agharazii, Mohsen ^a   Lebel, Marcel ^a   Larivière, Richard ^a  

^a Université Laval   (Canada)

Author keywords

Angiotensin AT1 receptor; Angiotensin II; Endothelin ETA receptor; Endothelin 1; Hydralazine; l NAME; Malignant hypertension; Nitric oxide; Renal injury

Indexed keywords

ANGIOTENSIN II; ATRASENTAN; ENDOTHELIN 1; HYDRALAZINE; LOSARTAN; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; GLOMERULOPATHY; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TUBULE NECROSIS; MALE; MALIGNANT HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SPRAGUE DAWLEY RAT; TREATMENT RESPONSE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIN-1; HYDRALAZINE; HYPERTENSION, MALIGNANT; KIDNEY FAILURE; LOSARTAN; MALE; NECROSIS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 62549120730     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.01.040     Document Type: Article

References (44)

1. Abassi Z.A., Klein H., Golomb E., and Keiser H.R. Regulation of the urinary excretion of endothelin in the rat. Am. J. Hypertens. 6 (1993) 453-457
2. Anderson S., Rennke H.G., and Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77 (1986) 1993-2000
3. Banting J.D., Friberg P., and Adams M.A. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J. Hypertens. 14 (1996) 975-981
4. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90 (1992) 278-281
5. Boffa J.J., Tharaux P.L., Placier S., Ardaillou R., Dussaule J.C., and Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 100 (1999) 1901-1908
6. Boffa J.J., Tharaux P.L., Dussaule J.C., and Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37 (2001) 490-496
7. Boffa J.J., Lu Y., Placier S., Stefanski A., Dussaule J.C., and Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol. 14 (2003) 1132-1144
8. D'Amours M., Lebel M., Grose J.H., and Larivière R. Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin-1 and angiotensin II. Can. J. Physiol. Pharmacol. 77 (1999) 8-16
9. De Gennaro Colonna V., Rigamonti A., Fioretti S., Bonomo S., Manfredi B., Ferrario P., Bianchi M., Berti F., Muller E.E., and Rossoni G. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in l-NAME-induced hypertensive rats. Eur. J. Pharmacol. 516 (2005) 253-259
10. De Gennaro Colonna V., Fioretti S., Rigamonti A., Bonomo S., Manfredi B., Muller E.E., Berti F., and Rossoni G. Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in l-NAME-induced hypertensive rats by a kinin-dependent mechanism. J. Hypertens. 24 (2006) 95-102
11. Deng X., Welch W.J., and Wilcox C.S. Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension. 27 (1996) 1173-1179
12. Dumont Y., D'Amours M., Lebel M., and Larivière R. Blood pressure-independent effects of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J. Hypertens. 19 (2001) 1479-1487
13. Dumont Y., D'Amours M., Lebel M., and Larivière R. Supplementation with a low dose of l-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol. Dial. Transplant. 16 (2001) 746-754
14. Erdely A., Freshour G., and Baylis C. Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar-Furth rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2006) R66-R72
15. Fernandez-Rivas A., Garcia-Estan J., and Vargas F. Effects of chronic increased salt intake on nitric oxide synthesis inhibition-induced hypertension. J. Hypertens. 13 (1995) 123-128
16. Fujihara C.K., De Nucci G., and Zatz R. Do ETA receptor participate in the hemodynamic and renal effects of chronic nitric oxide blockade?. J. Cardiovasc. Pharmacol. 26 suppl. 3 (1995) S462-S465
17. Graciano M.L., Cavaglieri Rde C., Delle H., Dominguez W.V., Casarini D.E., Malheiros D.M., and Noronha I.L. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J. Am. Soc. Nephrol. 15 (2004) 1805-1815
18. Kakinuma Y., Kawamura T., Bills T., Yoshioka T., Ichikawa I., and Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 42 (1992) 46-55
19. Kashiwagi M., Shinozaki M., Hirakata H., Tamaki K., Hirano T., Tokumoto M., Goto H., Okuda S., and Fujishima M. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J. Am. Soc. Nephrol. 11 (2000) 616-624
20. Lafayette R.A., Mayer G., Park S.K., and Meyer T.W. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 90 (1992) 766-771
21. Larivière R., and Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can. J. Physiol. Pharmacol. 81 (2003) 607-621
22. Larivière R., Lebel M., Kingma I., Grose J.H., and Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. 11 (1998) 989-997
23. Lavoie P., Robitaille G., Agharazii M., Ledbetter S., Lebel M., and Larivière R. Neutralization of transforming growth factor-b attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 23 (2005) 1895-1903
24. Lebel M., Grose J.H., Kingma I., and Langlois S. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients: effect of subcutaneous erythropoietin replacement therapy. Clin. Exper. Hypertens. 16 (1994) 565-575
25. Lebel M., Rodrigue M.E., Agharazii M., and Lariviere R. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am. J. Hypertens. 19 (2006) 1286-1292
26. Matsuguma K., Ueda S., Yamagishi S., Matsumoto Y., Kaneyuki U., Shibata R., Fujimura T., Matsuoka H., Kimoto M., Kato S., Imaizumi T., and Okuda S. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J. Am. Soc. Nephrol. 17 (2006) 2176-2183
27. Michel J.B., Xu Y., Blot S., Philippe M., and Chatellier G. Improved survival in rats administered NG-nitro l-arginine methyl ester due to converting enzyme inhibition. J. Cardiovasc. Pharmacol. 28 (1996) 142-148
28. Morris S.T., McMurray J.J., Spiers A., and Jardine A.G. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 60 (2001) 1077-1082
29. Nakamura T., Ohyama Y., Masuda H., Kurashina T., Saito Y., Kato T., Sumino H., Sato K., Sakamaki T., Sasaki A., and Nagai R. Chronic blockade of nitric oxide synthesis increases urinary endothelin-1 excretion. J. Hypertens. 15 (1997) 373-381
30. Pollock D.M., and Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am. J. Physiol. 275 (1998) R1719-R1723
31. Pollock D.M., Polakowski J.S., Divish B.J., and Opgenorth T.J. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21 (1993) 660-666
32. Qiu C., and Baylis C. Endothelin and angiotensin mediate most glomerular responses to nitric oxide inhibition. Kidney Int. 55 (1999) 2390-2396
33. Qiu C., Muchant D., Beierwaltes W.H., Racusen L., and Baylis C. Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension 31 (1998) 21-26
34. Ribeiro M.O., Antunes E., De Nucci G., Lovisolo S.M., and Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 20 (1992) 298-303
35. Rodrigue M.E., Moreau C., Larivière R., and Lebel M. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J. Cardiovasc. Pharmacol. 41 (2003) 388-395
36. Sika M., Lewis J., Douglas J., Erlinger T., Dowie D., Lipkowitz M., Lash J., Cornish-Zirker D., Peterson G., Toto R., Kusek J., Appel L., Kendrick C., and Gassman J. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am. J. Kidney Dis. 50 (2007) 78-89
37. Takemoto M., Egashira K., Usui M., Numaguchi K., Tomita H., Tsutsui H., Shimokawa H., Sueishi K., and Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structure changes induced by long-term blockade of nitric oxide synthesis in rats. J. Clin. Invest. 99 (1997) 278-287
38. Usui M., Egashira K., Tomita H., Koyanagi M., Katoh M., Shimokawa H., Takeya M., Yoshimura T., Matsushima K., and Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 101 (2000) 305-310
39. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 339 (1992) 572-575
40. van Dokkum R.P.E., Jacob H.J., and Provoost A.P. Genetic differences define severity of renal damage after l-NAME-induced hypertension in rats. J. Am. Soc. Nephrol. 9 (1998) 363-371
41. Vandermeersch S., Stefanovic V., Hus-Citharel A., Ardaillou R., Dussaule J.C., and Chansel D. AT1 receptor expression in glomeruli from NO-deficient rats. Nephron Exp. Nephrol. 95 (2003) e119-e128
42. Verhagen A.M.G., Rabelink T.J., Braam B., Opgenorth T.J., Grone H.J., Koomans H.A., and Joles J.A. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J. Am. Soc. Nephrol. 9 (1998) 755-762
43. Ying L., Flamant M., Vandermeersch S., Boffa J.J., Chatziantoniou C., Dussaule J.C., and Chansel D. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension. 42 (2003) 937-944
44. Zhou X., Matavelli L.C., Ono H., and Frohlich E.D. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in l-NAME/SHR. Am. J. Physiol. Renal Physiol. 289 (2005) F871-F879